Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinicsort descending Alpha Clinic Contact Trial Sponsor Disease Indication Clinical Trial Name Status of Enrollment Learn More
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
Behnam Badie, MD;
626-256-4673
bbadie@coh.org
City of Hope Cancer - Brain Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
newing@coh.org
Sangamo Therapeutics Hemophilia A Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A Recruiting
City of Hope
Myo Htut, MD
626-218-2405 ext 82405
mhtut@coh.org
Juno Therapeutics Cancer - Myeloma Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Adaptimmune Cancer - Myeloma NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma Recruiting
City of Hope
Joseph Rosenthal, MD
626-256-4673 ext 88442
jrosenthal@coh.org
City of Hope Sickle Cell Disease Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Fatemeh Bidmeshki
626-218-9393
fbidmeshki@coh.org
City of Hope Cancer - Brain HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Hormoz Babaei Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Celgene Cancer - Lymphoma An Exploratory Phase 1/2 Trial to Evaluate the Safety and Efficacy of JCAR017 Combinations in Subjects with Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting
City of Hope
Alex Herrera, MD
626-218-2405
aherrera@coh.org
Kite Pharma Cancer - Lymphoma Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma (ZUMA-12) Recruiting
City of Hope
Cheryl De Guzman
626-218-5613
CDeGuzman@coh.org
Children's Hospital Los Angeles Infection After Stem Cell Transplant Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Teresa Kim
626-218-0263
teresakim@coh.org
City of Hope Sickle Cell Disease A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant Recruiting
City of Hope
Anthony Stein, MD
626-218-2405
stein@coh.org
Precision BioSciences, Inc. Cancer - Lymphoma Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Cara Nolan
626-218-3241
canolan@coh.org
Juno Therapeutics Cancer - Lymphoma An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004) Recruiting
City of Hope
Leslie Popplewell, MD
626-218-2405
lpopplew@coh.org
Novartis Pharmaceuticals Cancer - Lymphona Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA) Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
​newing@coh.org
Sangamo Therapeutics Hemophilia B Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B Recruiting
City of Hope
Rie Miyahira
626-256-4673 ext 80032
rmiyahira@coh.org
Angiocrine Bioscience Cancer - Leukemia A Phase 1B, Open Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation Recruiting
City of Hope
Karen Reckamp, MD
626-218-9200
kreckamp@coh.org
Glaxo Smith Kline (GSK) Cancer - Lung Pilot Immunotherapy Study With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Lymphoma Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
UCSF
Romobia Hutchinson
415-476-9326
romobia.hutchinson@ucsf.edu
UCSF Blood Disorder - Alpha Thalassemia Major In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) Recruiting
UCSF
& UCLA
Marci Moriarty, BSN, RN
510-428-3885 ext 5396
mmoriarty@mail.cho.org
Bruck Habtemariam
310-794-0242
bhabtemariam@mednet.ucla.edu
Sangamo Therapeutics Blood Disorder - Beta-Thalassemia A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) Recruiting
UCSF
Hanjing Zhou
415-502-7434
hanging.zhou@ucsf.edu
Department of Defense Acute Respiratory Distress Syndrome (ARDS) A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma Recruiting
UCSF
James Aguila
415-502-8075
James.Aguila@ucsf.edu
Poseida Therapeutics, Inc. Multiple Myeloma Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) Recruiting
UCSF
Rebecca Hoh
415.476.4082 ext. 139
Rebecca.Hoh@ucsf.edu
Case Western Reserve University HIV A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) Recruiting
UCSF
Kenny Truong
(415) 502-2080
Kenny.Truong@ucsf.edu
UCSF Graft versus Host Disease (GvHD) An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients Recruiting
UCSF
Weston Preising
415-514-7975
hdfccc.cip.ucsf.edu
PACT Pharma Cancer – Solid Tumor A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Recruiting
UCSF
Cyrus Bascon
510-428-3885 ext 5396
CBascon@mail.cho.org
bluebird bio Sickle Cell Disease A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease Recruiting
UCSF
& UC Davis
Hanjing Zhou
415-502-7434
hanging.zhou@ucsf.edu
COVID-19/ARDS Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) Recruiting
UCSF
Julie DeCaris
510-428-3885 ext 2739
jdecaris@mail.cho.org
Seattle Children's Hospital Foundation Cancer - Leukemia A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia Recruiting
UCSF
Carol Fraser-Brown
415-476-2188
carol.fraser-browne@ucsf.edu
Stanford University Severe Combined Innunodeficiency (SCID) AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients Recruiting
UCSF
Julie DeCaris
510-428-3885. ext.2739
jdecaris@mail.cho.org
Bioverativ Therapeutics, Inc Sickle Cell Disease A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Eye - Retinopathy Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis B-Cell Leukemia A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Tongue Dysphagia Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Muscle - Duchenne Muscular Dystrophy A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) Recruiting
UC Davis
& UCSD & UCSF
Deborah Stewart
916-703-9118
distewart@ucdavis.edu
UC Davis HIV & Lyimphoma A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Nohla Therapeutics Cancer – Leukemia Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML Recruiting
UC Davis
Jane McCluskepy
916-703-9302
jmccluskey@ucdavis.edu
Medeor Therapuetics Kidney Transplant Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
UC Davis Cancer - Lymphoma (HIV-Related) Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Pluristem Ltd. Muscle Injury - hip fracture Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Kite Pharma Advanced Cancer A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers Recruiting
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio. EBV-PTLD Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) Recruiting

Pages

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News